Immunotherapies have substantially improved the prognosis of patients with haematological malignancies. While clinical trial data suggest durable complete response rates, markers associated with non-response to treatment are still poorly described. The identification of predictive markers using demographic, physiologic, biologic, immunologic data as well as patients' treatment history, might enable the optimization of therapeutic sequences and the reduction of treatment toxicity. This study aim to assess markers of toxicity and response following an immunotherapy in patients with a haematological malignancy using real life data. It will allow the development of clinical and therapeutic benchmarks to guide medical decisions in relation to the therapeutic strategies to be implemented for patients benefiting from real-life conditions, in addition to the results obtained in randomized studies.
Study Type
OBSERVATIONAL
Enrollment
249
Data collection
Assistance Publique - Hôpitaux de Paris (AP-HP) - Cochin Hospital
Paris, Île-de-France Region, France
Proportion of complete response
Treatment response : Explore the proportion of complete response
Time frame: Through study completion, an average of 1 year
Proportion of partial response
Treatment response : Explore the proportion of partial response
Time frame: Through study completion, an average of 1 year
Proportion of stable disease
Treatment response : Explore the proportion of stable disease
Time frame: Through study completion, an average of 1 year
Proportion of progress disease
Treatment response : Explore the proportion of progress disease
Time frame: Through study completion, an average of 1 year
Incidence of grade III adverse events
Toxicity : Explore the cumulative incidence of grade III and IV adverse events
Time frame: Through study completion, an average of 1 year
Incidence of grade IV adverse events
Toxicity : Explore the cumulative incidence of grade III and IV adverse events
Time frame: Through study completion, an average of 1 year
Interruption rates of immunotherapy
Toxicity : Explore the interruption and discontinuation rates of immunotherapy
Time frame: Through study completion, an average of 1 year
Discontinuation rates of immunotherapy
Toxicity : Explore the interruption and discontinuation rates of immunotherapy
Time frame: Through study completion, an average of 1 year
Time interval between the date of initiation treatment and the date of first progression
Progression free survival
Time frame: Through study completion, an average of 1 year
Time interval between the date of initiation treatment and the date of death from any cause
Overall survival
Time frame: Through study completion, an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.